Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	24211-30-1
Formula :	C₁₇H₁₆O₅
M.W :	300.31
SMILES Code :	CC1=C2C(C(C[C@@H](C3=CC=C(C=C3)O)O2)=O)=C(C(C)=C1O)O
MDL No. :	MFCD28347824
InChI Key :	DYHOLQACRGJEHX-UHFFFAOYSA-N
Pubchem ID :	91144

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P280-P301+P312-P302+P352-P305+P351+P338

HepG2 cells	5, 10, 20 µM	1 hour	To evaluate the protective effect of Farrerol against H2O2-induced cytotoxicity, results showed that Farrerol pretreatment significantly suppressed cytotoxicity caused by H2O2 in a dose-dependent manner.	Int J Biol Sci. 2019 Jan 29;15(4):788-799.
RAW264.7 cells	25, 50, 100 µM	1 hour	Farrerol significantly reduced the production of inflammatory mediators (IL-1β, IL-6, TNF-α, COX-2, and iNOS) in LPS-induced RAW264.7 cells by suppressing AKT, ERK1/2, JNK1/2, and NF-κB p65 phosphorylation.	Int J Mol Sci. 2018 Jul 13;19(7):2037.
Mouse mammary epithelial cells (mMECs)	90, 110, 130 µM	1 hour pretreatment followed by LPS stimulation for 4 hours	Inhibited inflammatory response and phosphorylation of AKT, NF-κB p65, p38, and ERK1/2	Int J Mol Sci. 2018 Jun 14;19(6):1770.
Bone marrow-derived macrophages (BMDM)	20 µM	15 minutes	To investigate the inhibitory effect of FA on NLRP3 inflammasome activation in macrophages. Results showed that FA significantly reduced IL-1β release and caspase-1 activation.	Front Pharmacol. 2022 Apr 13;13:879232.
HepG2 cells	5, 10, 20 µM	18 hours	To evaluate the inhibitory effect of Farrerol on H2O2-induced ROS generation, results showed that Farrerol pretreatment significantly reduced H2O2-induced ROS generation in a dose-dependent manner.	Int J Biol Sci. 2019 Jan 29;15(4):788-799.
Human proximal tubule cells (HK-2)	5, 10, 20 µM	18 hours	Farrerol pretreatment significantly attenuated cisplatin-induced cytotoxicity, particularly at a concentration of 20 μM.	Front Physiol. 2019 Nov 26;10:1419.
Mouse tubular epithelial cells (MTECs)	5, 10, 20 µM	18 hours	Farrerol pretreatment significantly attenuated cisplatin-induced cytotoxicity, particularly at a concentration of 20 μM.	Front Physiol. 2019 Nov 26;10:1419.
Rat thoracic aorta vascular smooth muscle cells (VSMCs)	0.3–10 µM	2 hours pretreatment followed by 48 hours stimulation	Inhibited FBS-induced VSMC proliferation and DNA synthesis, associated with G1 cell cycle arrest, down-regulation of cell cycle proteins, and reduction in FBS-induced ERK1/2 phosphorylation	Acta Pharmacol Sin. 2011 Apr;32(4):433-40.
HaCaT cells	4.7 µM (IC50)	20 hours	Evaluate inhibition of Farrerol on VEGF-induced wound healing, results showed IC50 of 4.7 µM	Molecules. 2025 Jan 10;30(2):257.
HCA2-hTERT cells	0.1 µM	24 hours	Farrerol promoted the recruitment of RAD51 at DNA damage sites and accelerated γH2AX foci clearance via UCHL3	Nat Commun. 2023 Apr 3;14(1):1838.
HEK293 cells	20 µM	24 hours	Confirmed UCHL3 as the direct target of Farrerol via CETSA assay, Farrerol increased the thermal stability of UCHL3	Nat Commun. 2023 Apr 3;14(1):1838.
Mouse embryonic stem cells (ESCs)	0.1, 1, 5, 10 µM	24 hours	Significantly enhances SpCRISPR/Cas9-mediated gene targeting efficiency	Elife. 2020 Jul 9;9:e56008.
HEK 293FT cells	0.1, 1, 5, 10 µM	24 hours	Promotes SpCRISPR/Cas9-mediated gene targeting efficiency	Elife. 2020 Jul 9;9:e56008.
Fibroblasts	20 µM	24 hours	Farrerol significantly inhibited Ang II-induced fibroblast migration and proliferation and reduced the expression of Collagen III and α-SMA.	Front Pharmacol. 2023 Jan 4;13:1079251.
Neonatal rat cardiomyocytes (NRCM)	20 µM	24 hours	Farrerol reduced the Ang II-induced increase in cardiomyocyte surface area and decreased mitochondrial ROS levels.	Front Pharmacol. 2023 Jan 4;13:1079251.
Human renal tubular epithelial cells (HK-2)	20 µM	24 hours	To evaluate the effect of Farrerol on the expression of Nrf2 and PINK1	Front Pharmacol. 2021 Nov 11;12:768700.
HepG2 cells	20 µM	24 hours	To investigate the effect of Farrerol on PAOA-induced lipid accumulation in HepG2 cells. Results showed that Farrerol reduced lipid accumulation by targeting PTPN1 and decreasing INSR dephosphorylation.	J Cell Mol Med. 2024 Sep;28(18):e70096.
Rat tenocytes	1, 5, 10, 20 and 40 μ M	24 hours	To evaluate the protective effect of Farrerol against RSL3-induced ferroptosis. Results showed that Farrerol at 10-40 μM concentrations was non-toxic and significantly inhibited RSL3-induced cell death and lipid peroxidation.	J Cell Mol Med. 2022 Jun;26(12):3483-3494.
RAW264.3 cells	1 µM, 10 µM, 25 µM	24 hours	Evaluate inhibition of Farrerol on VEGF-induced NF-κB activity, results showed dose-dependent suppression	Molecules. 2025 Jan 10;30(2):257.
HaCaT cells	1 µM, 10 µM, 25 µM, 50 µM, 100 µM	24 hours	Evaluate cytotoxicity, results showed Farrerol did not induce significant apoptosis at concentrations up to 100 µM	Molecules. 2025 Jan 10;30(2):257.
EA.hy926 cells	40-160 µM	24 or 48 hours	FA did not significantly affect the viability of EA.hy926 cells.	Int J Mol Sci. 2021 Aug 30;22(17):9400.
SKOV3 cells	40-160 µM	24 or 48 hours	FA decreased the viability of SKOV3 cells in a dose- and time-dependent manner, inducing G2/M cell cycle arrest and apoptosis.	Int J Mol Sci. 2021 Aug 30;22(17):9400.
A549 cells	0-64 µg/mL	3 hours	Evaluate the effect of Farrerol on the survival of A549 cells infected with MRSA USA300. Results showed that Farrerol significantly reduced LDH release, indicating decreased cell damage.	Antimicrob Agents Chemother. 2025 Apr 2;69(4):e0155124.
Rat liver microsomes	50 µM	60 minutes	To study the metabolites of Farrerol, 15 in vitro metabolites were identified	Molecules. 2019 Sep 24;24(19):3470.
3T3-L1 cells	15 or 30 µM	8 days	FA significantly increased adipocyte differentiation and intracellular lipid accumulation, and reversed TNF-α-mediated lipolysis.	Int J Mol Sci. 2021 Aug 30;22(17):9400.
Neofusicoccum laricinum	0.10 g/L, 0.25 g/L, 0.5 g/L, 1 g/L, 2 g/L	8 days	Evaluate the inhibitory effect of Farrerol on Neofusicoccum laricinum. The results showed that the inhibitory effect increased with the concentration of Farrerol, with 2 g/L achieving nearly 100% inhibition rate.	Plants (Basel). 2024 Oct 28;13(21):3004.
Rat aortic vascular smooth muscle cells (VSMCs)	14.02 µM		To study the effect of Farrerol on L-type voltage-gated Ca2+ channels (LVGC) using whole-cell patch clamp, results showed Farrerol significantly inhibited Ca2+ influx current.	Int J Mol Sci. 2014 Apr 17;15(4):6641-56.

Mice	Embryo model	Added to culture medium	0.05, 0.1 μM	24 hours	Improves SpCRISPR/Cas9-mediated gene targeting efficiency and supports efficient generation of gene-targeted mice	Elife. 2020 Jul 9;9:e56008.
C57BL/6J mice	Angiotensin II (Ang II)-induced cardiac remodeling model	Intraperitoneal injection	10 mg/kg	Once daily for 2 weeks	Farrerol inhibited Ang II-induced cardiac hypertrophy, inflammation, fibrosis, and oxidative stress, and improved cardiac function.	Front Pharmacol. 2023 Jan 4;13:1079251.
C57BL/6 wild-type and Nrf2 knockout mice	Cisplatin-induced chronic kidney disease (CKD) model	Intraperitoneal injection	10 mg/kg	Once daily until the day of harvest or 5 days after the second cisplatin injection	To evaluate the protective effect of Farrerol on cisplatin-induced CKD and its mechanism	Front Pharmacol. 2021 Nov 11;12:768700.
C57BL/6J mice	Myocardial ischemia/reperfusion (I/R) injury model	Intraperitoneal injection	10 mg/kg or 40 mg/kg	Once daily for 7 days	To investigate the protective effect of FA on myocardial I/R injury. Results showed that FA significantly alleviated myocardial tissue damage, reduced the secretion of myocardial injury factors (CK-MB, LDH, troponin-1, and NT-proBNP), and inhibited the release of inflammatory factors (IL-1β, IL-6, and TNF-α).	Front Pharmacol. 2022 Apr 13;13:879232.
Sprague-Dawley rats	Collagenase-induced tendinopathy model	Local injection	2 µg/100 μl	Once a week for 4 weeks	To evaluate the therapeutic effect of Farrerol on tendinopathy. Results showed that Farrerol significantly reduced inflammatory cell infiltration, promoted tenogenesis, and improved tendon mechanical properties. Additionally, Farrerol alleviated tendinopathy by inhibiting iron accumulation and ferroptosis.	J Cell Mol Med. 2022 Jun;26(12):3483-3494.
C57BL/6 mice	Cisplatin-induced acute kidney injury model	Intraperitoneal injection	20 mg/kg	Farrerol was administered 1 hour after cisplatin, and again at 24 and 48 hours, with sacrifice 24 hours after the last dose.	Farrerol significantly improved cisplatin-induced renal damage, including recovery of BUN, SCr, KIM-1, and NGAL levels, and alleviated pathological damage.	Front Physiol. 2019 Nov 26;10:1419.
Rats	Oral administration model	Oral	20 mg/kg	Single dose, sampling time from 0.083 to 24 hours	To study the in vivo metabolism of Farrerol, 42 in vivo metabolites were identified	Molecules. 2019 Sep 24;24(19):3470.
BALB/c mice	LPS-induced mastitis model	Intraperitoneal injection	20, 30, 40 mg/kg	Second dose administered 12 h after LPS injection	Improved pathological injury of mammary gland, reduced MPO activity, inhibited pro-inflammatory mediators and phosphorylation of AKT, NF-κB p65, p38, and ERK1/2	Int J Mol Sci. 2018 Jun 14;19(6):1770.
B6 mice	APAP-induced hepatotoxicity model	Intraperitoneal injection	40 mg/kg	Twice, at 12 h and 1 h intervals	To evaluate the protective effect of Farrerol against APAP-induced hepatotoxicity, results showed that Farrerol significantly reduced mortality, histopathological liver changes, and ALT and AST levels caused by APAP.	Int J Biol Sci. 2019 Jan 29;15(4):788-799.
C57BL/6J mice	High-fat diet-induced MAFLD model	Intraperitoneal injection	40 mg/kg	Once daily for 8 weeks	To investigate the effect of Farrerol on insulin resistance and hepatic steatosis in high-fat diet-induced MAFLD mice. Results showed that Farrerol improved insulin sensitivity, glucose tolerance, and alleviated hepatic steatosis and lipid accumulation.	J Cell Mol Med. 2024 Sep;28(18):e70096.
C57BL/6 mice	TNBS-induced colitis model	Oral	45 mg/kg	Once daily for 3 days	Farrerol significantly improved weight change, clinical scores, colon length, and intestinal epithelium barrier damage, and markedly decreased inflammatory cytokines production in TNBS-induced mice.	Int J Mol Sci. 2018 Jul 13;19(7):2037.
C57BL/6J mice	S. aureus-induced pneumonia model	Intraperitoneal injection	50 mg/kg	Every 12 hours for 96 hours	Evaluate the protective effects of Farrerol combined with cefepime in mice with S. aureus-induced pneumonia. Results showed that the combination therapy significantly improved survival rates, reduced bacterial load in the lungs, and ameliorated tissue damage.	Antimicrob Agents Chemother. 2025 Apr 2;69(4):e0155124.

{[proInfo.proName]}

CAS No.: 24211-30-1

{[proInfo.proName]}

CAS No.: 24211-30-1

Alternative Products

Product Details of Farrerol

Safety of Farrerol

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	3.33mL 0.67mL 0.33mL	16.65mL 3.33mL 1.66mL	33.30mL 6.66mL 3.33mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed